statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	474
SG - Singapore	159
VN - Vietnam	92
CN - Cina	75
IE - Irlanda	52
IT - Italia	51
BR - Brasile	45
DE - Germania	33
HK - Hong Kong	31
SE - Svezia	25
AT - Austria	22
NL - Olanda	19
FI - Finlandia	18
FR - Francia	18
GB - Regno Unito	16
ZA - Sudafrica	15
IN - India	10
BD - Bangladesh	9
AR - Argentina	6
EC - Ecuador	5
IQ - Iraq	5
RU - Federazione Russa	5
CA - Canada	4
IR - Iran	4
PK - Pakistan	4
PL - Polonia	4
BE - Belgio	3
CZ - Repubblica Ceca	3
ES - Italia	3
MX - Messico	3
VE - Venezuela	3
AE - Emirati Arabi Uniti	2
AL - Albania	2
CI - Costa d'Avorio	2
KG - Kirghizistan	2
LT - Lituania	2
MK - Macedonia	2
NP - Nepal	2
PY - Paraguay	2
SA - Arabia Saudita	2
TH - Thailandia	2
TR - Turchia	2
UA - Ucraina	2
UZ - Uzbekistan	2
AZ - Azerbaigian	1
BG - Bulgaria	1
BH - Bahrain	1
BO - Bolivia	1
DZ - Algeria	1
HR - Croazia	1
ID - Indonesia	1
JO - Giordania	1
JP - Giappone	1
KR - Corea	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
NO - Norvegia	1
PH - Filippine	1
RS - Serbia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	1.259

Nome	#
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab	202
Stage III and metastatic Lymph Node Ratio are the only independent prognostic factors in colorectal signet-ring cell carcinoma patients	158
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer	145
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity	141
Should patients on levothyroxine therapy be screened for pancreatic cancer?	141
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer	127
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5)	94
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review	92
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals	90
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study	90
Totale	1.280

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	4	0	0	0	0	0	0	0	0	0	0	2	2
2021/2022	23	0	1	2	0	1	0	7	1	1	0	1	9
2022/2023	205	10	28	9	15	10	19	6	18	66	4	11	9
2023/2024	106	8	7	6	3	7	19	9	7	1	8	9	22
2024/2025	300	17	11	12	25	26	32	17	17	26	36	28	53
2025/2026	611	70	38	78	64	98	49	64	18	92	40	0	0
Totale													1.280